Justlina 5 Tablet contains Linagliptin 5 mg, a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. Linagliptin works by enhancing the incretin system, which increases insulin secretion and decreases glucagon release in a glucose-dependent manner, thereby improving glycemic control without causing significant hypoglycemia. Justlina 5 is prescribed as monotherapy or as an adjunct to diet and exercise, and may be used in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin. The tablet is orally administered once daily, with or without food, providing convenience and improved patient adherence. Linagliptin is primarily eliminated via the enterohepatic system, making dose adjustment unnecessary in patients with renal impairment. Clinical studies have demonstrated that Justlina 5 effectively lowers HbA1c levels and fasting plasma glucose, contributing to better long-term glycemic management. Common adverse effects are generally mild and may include nasopharyngitis, headache, and upper respiratory tract infections. Justlina 5 should be used cautiously in patients with a history of pancreatitis and under medical supervision to monitor efficacy and safety. This medication is not indicated for type 1 diabetes or diabetic ketoacidosis.